Previous 10 | Next 10 |
Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George’s Respiratory Questionnaire (S...
Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesd...
2024-06-19 09:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Though risky, there are certainly plenty of penny stocks to buy that have the potential to significantly boost portfolio returns. Of course, patience and a growth-friendly market are requir...
2024-06-11 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable. However, despit...
2024-06-07 05:56:23 ET Summary Savara is a biotech company focusing on the treatment of autoimmune pulmonary alveolar proteinosis. The company's valuation will be heavily impacted by the results of its upcoming IMPALA-2 trial for its drug Molgramostim. The trial results are ex...
2024-06-02 06:49:06 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
2024-05-31 15:00:19 ET More on the markets Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight Hedge funds back at record exposure to Magnificent 7 S&am...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am PT/10:00am ET. A live webcast of the ...
Savara’s Partner, Trillium Health LLC, Presented Data on the Laboratory Blood Test for Diagnosing aPAP Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Societ...
2024-05-09 17:27:25 ET More on Savara JMP starts Savara at buy, cites market potential for lung disease drug Seeking Alpha’s Quant Rating on Savara Historical earnings data for Savara Financial information for Savara Read the full article on ...
News, Short Squeeze, Breakout and More Instantly...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, fo...
2024-06-27 10:15:02 ET Guggenheim analyst issues BUY recommendation for SVRA on June 27, 2024 08:56AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-27 10:00:08 ET Vamil Divan from Guggenheim issued a price target of $10.00 for SVRA on 2024-06-27 08:56:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $10.50 wi...